Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2511-2515

  Taplin, Mary Ellen ^a   Bubley, Glenn J ^b   Ko, Yoo Joung ^c   Small, Eric J ^d   Upton, Melissa ^b   Rajeshkumar, Barur ^a   Balk, Steven P ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE;

ARTICLE; CELL SURVIVAL; DRUG EFFECT; GENE MUTATION; GENETIC TRANSCRIPTION; HORMONAL REGULATION; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR BLOCKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BONE MARROW; BONE MARROW NEOPLASMS; CODON; DNA MUTATIONAL ANALYSIS; FLUTAMIDE; HUMANS; MALE; MUTATION; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033152164     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Catalona, W. J. Management of cancer of the prostate [see comments]. N. Engl. J. Med., 331: 996-1004, 1994.
2. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G., and Klocker, H. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol., 7: 1541-1550, 1993.
3. Gaddipati, J. P., McLeod, D. G., Heidenberg, H. B., Sesterhenn, I. A., Finger, M. J., Moul, J. W., and Srivastava, S. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res., 54: 2861-2864, 1994.
4. Suzuki, H., Sato, N., Watabe, Y., Masai, M., Seino, S., and Shimazaki, J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol., 46: 759-765, 1993.
5. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., and Balk, S. P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer [see comments]. N. Engl. J. Med., 332: 1393-1398, 1995.
6. Suzuki, H., Akakura, K., Komiya, A., Aida, S., Akimoto, S., and Shimazaki, J. Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome. Prostate, 29: 153-158, 1996.
7. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinanen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., and Kallioniemi, O. P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9: 401-406, 1995.
8. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C., Trapman, J., Brinkmann, A. O., and Mulder, E. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun., 173: 534-540, 1990.
9. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., and Mulder, E. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31: 2393-2399, 1992.
10. Fenton, M. A., Shuster, T. D., Fertig, A. M., Taplin, M-E., Kolvenbag, G., Bubley, G. J., and Balk, S. P. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer. Res., 3: 1383-1388, 1997.
11. Belanger, A., Giasson, M., Couture, J., Dupont, A., Cusan, L., and Labrie, F. Plasma levels of hydroxy-flutamide in patients with prostatic cancer receiving the combined hormonal therapy: an LHRH agonist and flutamide. Prostate, 12: 79-84, 1988.
12. Scher, H. I., and Kelly, W. K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J. Clin. Oncol., 11: 1566-1572, 1993.
13. Small, E. J., and Srinivas, S. The antiandrogen withdrawal syndrome. Experience in a large cohort of unselected patients with advanced prostate cancer. Cancer (Phila.), 76: 1428-1434, 1995.
14. Dupont, A., Gomez, J. L., Cusan, L., Koutsilieris, M., and Labrie, F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913, 1993.
15. Sartor, O., Cooper, M., Weinberger, M., Headlee, D., Thibault, A., Tompkins, A., Steinberg, S., Figg, W. D., Linehan, W. M., and Myers, C. E. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer [published erratum appears in J. Natl. Cancer Inst., 86: 463, 1994]. J. Natl. Cancer Inst., 86: 222-227, 1994.
16. Small, E. J., Baron, A., and Bok, R. Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer (Phila.), 80: 1755-1759, 1997.
17. Joyce, R., Fenton, M. A., Rode, P., Constantine, M., Gaynes, L., Kolvenbag, G., DeWolf, W., Balk, S., Taplin, M. E., and Bubley, G. J. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol., 159: 149-153, 1998.
18. Scher, H. I., Liebertz, C., Kelly, W. K., Mazumdar, M., Brett, C., Schwartz, L., Kolvenbag, G., Shapiro, L., and Schwartz, M. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease J. Clin. Oncol., 15: 2928-2938, 1997.
19. Caubet, J. F., Tosteson, T. D., Dong, E. W., Naylon, E. M., Whiting, G. W., Ernstoff, M. S., and Ross, S. D. Maximum androgen blockade in advanced prostate cancer: a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology, 49: 71-78, 1997.
20. Eisenberger, M. A., Blumenstein, B. A., Crawford, E. D., Miller, G., McLeod, D. G., Loehrer, P. J., Wilding, G., Sears, K., Culkin, D. J., Thompson, I. M., Jr., Bueschen, A. J., and Lowe, B. A. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med., 339: 1036-1042, 1998.
21. Tan, J., Sharief, Y., Hamil, K. G., Gregory, C. W., Zang, D. Y., Sar, M., Gumerlock, P. H., deVere White, R. W., Pretlow, T. G., Harris, S. E, Wilson, E. M., Mohler, J. L., and French, F. S. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol. Endocrinol., 11: 450-459, 1997.